Kaszczewska Monika, Popow Michał, Chudziński Witold, Kaszczewska Joanna, Bogdańska Magdalena, Podgórska Joanna, Czarniecka Agnieszka, Gałązka Zbigniew
Department of General, Endocrine and Vascular Surgery, Medical University of Warsaw, Warsaw, Poland.
Department of Internal Diseases and Endocrinology, Medical University of Warsaw, Warsaw, Poland.
Am J Case Rep. 2021 Mar 11;22:e930301. doi: 10.12659/AJCR.930301.
BACKGROUND Parathyroid carcinoma (PC), accounting for 0.005% of all cancers, is responsible for less than 1% of all cases of primary hyperparathyroidism, and equally affects males and females, usually in 4th or 5th decades of life. PC can occur sporadically and can be associated with congenital genetic syndromes such as hyperparathyroidism-jaw tumor syndrome (HPT-JT), isolated familial hyperparathyroidism, or multiple endocrine neoplasia 1 and 2 syndromes. Surgery is the main treatment, with a limited role of radio- and chemotherapy, which allows 49-77% of patients to survive 10 years. In this work we report the case of a patient with parathyroid carcinoma, whose treatment required 13 surgeries over a period of 27 years, together with radiotherapy and pharmacological treatment. CASE REPORT A 51-year-old woman was first diagnosed with primary hyperparathyroidism in 1993 at the age of 23. From 1993 to present, she underwent 13 surgeries and 33 courses of radiotherapy due to recurrent lesions, which initially had a character of parathyroid adenomas, then parathyromatosis, and finally were diagnosed as parathyroid carcinoma. The patient also required and currently requires complex pharmacological treatment to control the calcemia and manage the complications of the primary disease. Supervision by the multidisciplinary professional medical team allows the patient to lead a normal life with good control of the disease. CONCLUSIONS Parathyroid carcinoma is a rare disease with a number of complications; however, obtaining satisfactory long-term survival with acceptable quality of life is achievable.
甲状旁腺癌(PC)占所有癌症的0.005%,在所有原发性甲状旁腺功能亢进病例中占比不到1%,对男性和女性的影响相同,通常发生在40或50岁左右。PC可散发发生,也可与先天性遗传综合征相关,如甲状旁腺功能亢进-颌骨肿瘤综合征(HPT-JT)、孤立性家族性甲状旁腺功能亢进或多发性内分泌腺瘤1型和2型综合征。手术是主要治疗方法,放疗和化疗作用有限,这使得49%至77%的患者能存活10年。在本研究中,我们报告了一例甲状旁腺癌患者的病例,其治疗在27年期间需要进行13次手术,同时进行放疗和药物治疗。病例报告:一名51岁女性于1993年23岁时首次被诊断为原发性甲状旁腺功能亢进。从1993年至今,由于复发病变,她接受了13次手术和33个疗程的放疗,这些病变最初表现为甲状旁腺腺瘤特征,随后为甲状旁腺增生症,最终被诊断为甲状旁腺癌。该患者过去和现在都需要复杂的药物治疗来控制血钙水平并处理原发性疾病的并发症。多学科专业医疗团队的监督使患者能够在疾病得到良好控制的情况下过上正常生活。结论:甲状旁腺癌是一种罕见疾病,有多种并发症;然而,实现令人满意的长期生存并保持可接受的生活质量是可行的。